Artiva Biotherapeutics, Inc. ARTV Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$87.07M-3.8% | -$83.87M-5.9% | -$79.19M-5.4% | -$75.13M-4.8% | -$71.72M-9.7% | ||
| $2.64M+1.5% | $2.6M+2.0% | $2.55M+1.4% | $2.51M+1.5% | $2.47M+1.7% | ||
| $6.36M-6.7% | $6.82M-8.0% | $7.42M-3.6% | $7.69M+0.9% | $7.63M+9.3% | ||
| —— | $0+100% | -$569K0.0% | -$569K+30.5% | -$819K+20.8% | ||
| $1.01M+233% | -$760K— | —— | —— | —— | ||
| -$1.07M-153% | $2M+248% | -$1.35M-315% | $629K— | —— | ||
| —— | $191K+59.2% | $120K+141% | -$292K+16.1% | -$348K-178% | ||
| —— | —— | —— | —— | —— | ||
| -$77.86M-1.4% | -$76.75M-0.1% | -$76.68M-11.0% | -$69.09M-15.6% | -$59.79M-8.6% | ||
| $2.32M-10.4% | $2.59M+16.0% | $2.23M+29.2% | $1.73M+52.1% | $1.14M+76.8% | ||
| $32.8M-26.9% | $44.88M-14.0% | $52.19M-71.4% | $182.38M-3.2% | $188.49M+7.0% | ||
| $103.87M-6.3% | $110.87M+10.0% | $100.82M+20.6% | $83.6M+20.5% | $69.35M+23.1% | ||
| $68.76M+8.4% | $63.41M+36.6% | $46.41M+146% | -$100.5M+16.4% | -$120.27M+0.2% | ||
| —— | —— | —— | —— | —— | ||
| $132K0.0% | $132K+0.8% | $131K-4.4% | $137K— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$10.64M+26.7% | -$14.52M+51.9% | -$30.17M-441% | -$5.58M+68.3% | -$17.6M-32.6% | ||
| $1.36M-27.9% | $1.88M-28.5% | $2.63M-10.3% | $2.93M+8.8% | $2.7M+15.2% | ||
| —— | —— | -$29K— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $0— | $0+100% | -$977K+70.7% | -$3.33M+7.5% | ||
| $103.87M-6.3% | $110.87M+10.0% | $100.82M+20.6% | $83.6M+20.5% | $69.35M+23.1% | ||
| $132K0.0% | $132K+0.8% | $131K-4.4% | $137K— | —— | ||
| —— | $0-100% | $20K-99.2% | $2.62M— | —— | ||
| —— | —— | —— | —— | -$134K— | ||
| —— | —— | —— | —— | —— | ||
| —— | $0-100% | $54.1M-50.0% | $108.21M-33.3% | $162.31M-25.0% | ||
| —— | —— | —— | —— | $442K— | ||
| -$80.18M-1.1% | -$79.34M-0.5% | -$78.91M-11.4% | -$70.81M-16.2% | -$60.92M-9.4% | ||
| -$80.18M-1.1% | -$79.34M-0.5% | -$78.91M-11.4% | -$70.81M-16.2% | -$60.92M-9.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Artiva Biotherapeutics, Inc. generate?
- Artiva Biotherapeutics, Inc. (ARTV) generated -$77.9M in operating cash flow over the trailing twelve months.
- What is Artiva Biotherapeutics, Inc.'s free cash flow?
- After $2.3M of capital expenditures, Artiva Biotherapeutics, Inc.'s free cash flow was -$80.2M over the trailing twelve months, down 31.6% year over year.
- Where does Artiva Biotherapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Artiva Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.